Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Anktiva plus BCG Durable CR numbers

<< Previous

Bullboard Posts

Next >>

Comment by Donein25on Apr 25, 2024 8:32am

197 Views

Post# 36006677

RE:RE:RE:Anktiva plus BCG Durable CR numbers

agreed. Its a reasonable pathway and timetable. And the new mandates of 2 and 3 year surveillance for TLT seem to be in step with what FDA has told ImmunityBio for their approval. Too bad our share price does not take this into consideration as a likely sequence of events in the relatively near future. (more than a few small biotechs have been scooped up by big pharma a year in advance of AA).

<< Previous

Bullboard Posts

Next >>

These cold weather stocks are looking to heat up for winter